All Title Author
Keywords Abstract


Visceral Leishmaniasis and HIV Coinfection in East Africa

DOI: 10.1371/journal.pntd.0002869

Full-Text   Cite this paper   Add to My Lib

Abstract:

Visceral Leishmaniasis (VL) is an important protozoan opportunistic disease in HIV patients in endemic areas. East Africa is second to the Indian subcontinent in the global VL caseload and first in VL-HIV coinfection rate. Because of the alteration in the disease course, the diagnostic challenges, and the poor treatment responses, VL with HIV coinfection has become a very serious challenge in East Africa today. Field experience with the use of liposomal amphotericin B in combination with miltefosine, followed by secondary prophylaxis and antiretroviral drugs, looks promising. However, this needs to be confirmed through clinical trials. Better diagnostic and follow-up methods for relapse and prediction of relapse should also be looked for. Basic research to understand the immunological interaction of the two infections may ultimately help to improve the management of the coinfection.

References

[1]  van Griensven J, Diro E (2012) Visceral leishmaniasis. Infect Dis Clin North Am 26: 309–322 doi:10.1016/j.idc.2012.03.005.
[2]  Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671 doi: 10.1371/journal.pone.0035671.
[3]  Seaman J, Mercer AJ, Sondorp E (1996) The epidemic of visceral leishmaniasis in western upper Nile, Southern Sudan: Course and impact from 1984 to 1994. Int J Epidemiol 25: 862–871. doi: 10.1093/ije/25.4.862
[4]  Olivier M, Badaro R, Medrano FJ, Moreno J (2003) The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms. Ann Trop Med Parasitol 97 Suppl 1: 79–98 doi: 10.1179/000349803225002561.
[5]  Alvar J, Aparicio P, Aseffa A, den Boer M, Canavate C, et al. (2008) The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334–359 table. doi:10.1128/CMR.00061-07.
[6]  Jarvis JN, Lockwood DN (2013) Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin Infect Dis 26: 1–9 doi: 10.1097/QCO.0b013e32835c2198.
[7]  World Health Organization (2010 March 22) Control of the Leishmaniases. In: WHO Technical Report Series 949: Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010. Geneva, Swetzerland: World Health Organization.
[8]  Joint United Nations Programme on HIV/AIDS [UNAIDS] (2013) Global Report: UNAIDS report on the global AIDS epidemic. Available: http://www.unaids.org/en/media/unaids/co?ntentassets/documents/epidemiology/2013/?gr2013/UNAIDS_Global_Report_2013_en.pdf. Accessed 22 May 2014.
[9]  Merson MH, O'Malley J, Serwadda D, Apisuk C (2008) The history and challenge of HIV prevention. Lancet 372: 475–488 doi: 10.1016/S0140-6736(08)60884-3.
[10]  Ethiopian Health and Nutrition Research Institute (EHNRI) (2011) Report on the 2009 Round Antenatal Care Sentinel HIV Surveillance in Ethiopia. Available: http://www.ehnri.gov.et/newsletter/ANC%2?02009_Final_Report.pdf. Accessed 22 May 2014.
[11]  Federal Democratic Republic of Ethiopia (2012) Country progress report on HIV/AIDS response. Available: http://www.unaids.org/en/dataanalysis/kn?owyourresponse/countryprogressreports/20?12countries/GAP%20Report%202012.pdf. Accessed 22 May 2014.
[12]  Mengistu G, Ayele B (2007) Visceral leishmaniasis and HIV co-infection in patients admitted to Gondar University Hopsital, North West Ethiopia. Ethiop J Health Dev 21: 53–60. doi: 10.4314/ejhd.v21i1.10032
[13]  Argaw D, Mulugeta A, Herrero M, Nombela N, Teklu T, et al. (2013) Risk factors for visceral Leishmaniasis among residents and migrants in Kafta-Humera, Ethiopia. PLoS Negl Trop Dis 7: e2543 doi: 10.1371/journal.pntd.0002543.
[14]  Gelanew T, Kuhls K, Hurissa Z, Weldegebreal T, Hailu W, et al. (2010) Inference of population structure of Leishmania donovani strains isolated from different Ethiopian visceral leishmaniasis endemic areas. PLoS Negl Trop Dis 4: e889 doi: 10.1371/journal.pntd.0000889.
[15]  Malaria Consortium (2010) Leishmaniasis control in eastern Africa: Past and present efforts and future needs. Situation and gap analysis. Available: http://www.malariaconsortium.org/userfil?es/file/NTD%20Resources/VL%20EA%20Situat?ion%20Analysis%20Fina_Janl.pdf. Accessed 22 May 2014.
[16]  Catorce G (2010) Leishmania infantum/HIV co-infection: cuteneous lesions following treatment of visceral leishmaniasis. Ann Dermatol Venereol 133: 39–42.
[17]  Fenske S, Stellbrink HJ, Albrecht H, Greten H (1991) Visceral leishmaniasis in an HIV-infected patient: clinical features and response to treatment. Klin Wochenschr 69: 793–796. doi: 10.1007/bf01744270
[18]  Garcia-Samaniego J, Laguna F (1997) [Intestinal leishmaniasis in AIDS patients]. Rev Esp Enferm Dig 89: 145.
[19]  Hurissa Z, Gebre-Silassie S, Hailu W, Tefera T, Lalloo DG, et al. (2010) Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health 15: 848–855 doi: 10.1111/j.1365-3156.2010.02550.x.
[20]  Gelanew T, Hurissa Z, Diro E, Kassahun A, Kuhls K, et al. (2011) Disseminated cutaneous leishmaniasis resembling post-kala-azar dermal leishmaniasis caused by Leishmania donovani in three patients co-infected with visceral leishmaniasis and human immunodeficiency virus/acquired immunodeficiency syndrome in Ethiopia. Am J Trop Med Hyg 84: 906–912 doi:10.4269/ajtmh.2011.11-0055.
[21]  Diro E, Hurissa Z, van Griensven J, Hailu A (2011) Unusual presentations of visceral leishmania in the era of HIV. In: Proceedings of the 16th International Conference on AIDS and STIs in Africa (ICASA); 4–8 December 2011; Addis Ababa, Ethiopia.
[22]  Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM (2003) Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 3: 87–98. doi: 10.1016/s1473-3099(03)00517-6
[23]  Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, et al. (2001) Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 95: 668–672. doi: 10.1016/s0035-9203(01)90110-5
[24]  Chappuis F, Rijal S, Soto A, Menten J, Boelaert M (2006) A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ 333: 723 doi: 10.1136/bmj.38917.503056.7C.
[25]  Chappuis F, Mueller Y, Nguimfack A, Rwakimari JB, Couffignal S, et al. (2005) Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda. J Clin Microbiol 43: 5973–5977 doi: 10.1128/JCM.43.12.5973-5977.2005 [doi].
[26]  Cunningham J, Hasker E, Das P, El SS, Goto H, et al. (2012) A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis 55: 1312–1319 doi:10.1093/cid/cis716.
[27]  Diro E, Techane Y, Tefera T, Assefa Y, Kebede T, et al. (2007) Field evaluation of FD-DAT, rK39 dipstick and KATEX (urine latex agglutination) for diagnosis of visceral leishmaniasis in northwest Ethiopia. Trans R Soc Trop Med Hyg 908–914 doi: 10.1016/j.trstmh.2007.05.002.
[28]  ter Horst R, Tefera T, Assefa G, Ebrahim AZ, Davidson RN, et al. (2009) Field evaluation of rK39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia. Am J Trop Med Hyg 80: 929–934.
[29]  Adams ER, Schoone GJ, Ageed AF, Safi SE, Schallig HD (2010) Development of a reverse transcriptase loop-mediated isothermal amplification (LAMP) assay for the sensitive detection of Leishmania parasites in clinical samples. Am J Trop Med Hyg 82: 591–596 doi: 10.4269/ajtmh.2010.09-0369.
[30]  Hailu A, Berhe N (2002) The performance of direct agglutination tests (DAT) in the diagnosis of visceral leishmaniasis among Ethiopian patients with HIV co-infection. Ann Trop Med Parasitol 96: 25–30. doi: 10.1179/000349802125000475
[31]  Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, et al. (2006) A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 43: 357–364 doi: 10.1086/505217.
[32]  Deniau M, Canavate C, Faraut-Gambarelli F, Marty P (2003) The biological diagnosis of leishmaniasis in HIV-infected patients. Ann Trop Med Parasitol 97 Suppl 1: 115–133 doi: 10.1179/000349803225002598.
[33]  Izri MA, Deniau M, Briere C, Rivollet D, Petithory JC, et al. (1996) Leishmaniasis in AIDS patients: results of leukocytoconcentration, a fast biological method of diagnosis. Bull World Health Organ 74: 91–93.
[34]  Yansouni CP, Diro E, Lynen L, van Griensven J, Takele Y, et al.. (2012) Diagnosis of visceral leishmaniasis using peripheral blood microscopy in Ethiopia: a phase-III diagnostic study evaluating 3 parasite concentration techniques compared to tissue aspiration. In: Proceedings of the 61st Annual Meeting of the American Society of Tropical Medicine and Hygiene, 11–15 November 2012; Atlanta, Georgia, United States.
[35]  Cota GF, de Sousa MR, Demarqui FN, Rabello A (2012) The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis. PLoS Negl Trop Dis 6: e1665 doi: 10.1371/journal.pntd.0001665.
[36]  Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, et al. (2010) Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis 4: e709 doi: 10.1371/journal.pntd.0000709.
[37]  Musa AM, Younis B, Fadlalla A, Royce C, Balasegaram M, et al. (2010) Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl Trop Dis 4: e855 doi: 10.1371/journal.pntd.0000855.
[38]  Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, et al. (2011) Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 53: e152–e158 doi: 10.1093/cid/cir674.
[39]  Diro E, Lynen L, Mohammed R, Boelaert M, Hailu A, et al.. (2013) Increasing parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected patients in East Africa. In: Proceedings of the Fifth World Leishmaniasis Congress; 13–17 May 2013; Porto de Galhinas, Brazil.
[40]  Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, et al. (2011) Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 53: e91–e98 doi: 10.1093/cid/cir521.
[41]  Ritmeijer K (2013) Old and new treatments for HIV/VL co-infection. In: Proceedings of the Fifth World Leishmaniasis Congress, 13–17 May 2013; Porto de Galhinas, Brazil.
[42]  Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, et al. (2012) Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl Trop Dis 6: e1674 doi: 10.1371/journal.pntd.0001674.
[43]  Federal Ministry of Health, Ethiopia (2013) Guidelines for diagnosis, treatment and prevention of leishmaniasis in Ethiopia, 2nd edition. Addis Adaba, Ethiopia: Federal Ministry of Health, Ethiopia.
[44]  Hailu W, Weldegebreal T, Hurissa Z, Tafes H, Omollo R, et al. (2010) Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection. Trans R Soc Trop Med Hyg 104: 706–712 doi: 10.1016/j.trstmh.2010.07.007.
[45]  ter HR, Collin SM, Ritmeijer K, Bogale A, Davidson RN (2008) Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 46: 1702–1709 doi: 10.1086/587899.
[46]  Cota GF, de Sousa MR, Rabello A (2011) Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis 5: e1153 doi: 10.1371/journal.pntd.0001153.
[47]  Lopez-Velez R, Videla S, Marquez M, Boix V, Jimenez-Mejias ME, et al. (2004) Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 53: 540–543 doi: 10.1093/jac/dkh084.
[48]  Calza L, Marinacci G, Manfredi R, Colangeli V, Fortunato L, et al. (2001) Pentamidine isethionate as treatment and secondary prophylaxis for disseminated cutaneous leishmaniasis during HIV infection: case report. J Chemother 13: 653–657. doi: 10.1179/joc.2001.13.6.653
[49]  Ena J, Amador C, Pasquau F, Carbonell C, Benito C, et al. (1994) Once-a-month administration of intravenous pentamidine to patients infected with human immunodeficiency virus as prophylaxis for Pneumocystis carinii pneumonia. Clin Infect Dis 18: 901–904. doi: 10.1093/clinids/18.6.901
[50]  Yeung KT, Chan M, Chan CK (1996) The safety of i.v. pentamidine administered in an ambulatory setting. Chest 110: 136–140. doi: 10.1378/chest.110.1.136
[51]  ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN (2008) Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 46: 1702–1709 doi: 10.1086/587899.
[52]  Petter A, Shetty-Lee A, Kofler G, Huemer HP, Larcher C (2001) Visceral leishmaniasis in an AIDS patient on successful antiretroviral therapy: failure of parasite eradication despite increase in CD4+ T-cell count but low CD8+ T-cell count. Scand J Infect Dis 33: 236–238. doi: 10.1080/00365540151061049
[53]  Ramos A, Cruz I, Munez E, Salas C, Fernandez A, et al. (2008) Post-kala-azar dermal Leishmaniasis and uveitis in an HIV-positive patient. Infection 36: 184–186 doi: 10.1007/s15010-007-6279-5.
[54]  Antinori S, Longhi E, Bestetti G, Piolini R, Acquaviva V, et al. (2007) Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol 157: 1032–1036 doi: 10.1111/j.1365-2133.2007.08157.x.
[55]  Bittencourt A, Silva N, Straatmann A, Nunes VL, Follador I, et al. (2003) Post-kala-azar dermal leishmaniasis associated with AIDS. Braz J Infect Dis 7: 229–233. doi: 10.1590/s1413-86702003000300009
[56]  Stark D, Pett S, Marriott D, Harkness J (2006) Post-kala-azar dermal leishmaniasis due to Leishmania infantum in a human immunodeficiency virus type 1-infected patient. J Clin Microbiol 44: 1178–1180 doi: 10.1128/JCM.44.3.1178-1180.2006.
[57]  Ridolfo AL, Gervasoni C, Antinori S, Pizzuto M, Santambrogio S, et al. (2000) Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. J Infect 40: 199–202. doi: 10.1053/jinf.1999.0630
[58]  Gilad J, Borer A, Hallel-Halevy D, Riesenberg K, Alkan M, et al. (2001) Post-kala-azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection. Isr Med Assoc J 3: 451–452.
[59]  Khalil EA, Khidir SA, Musa AM, Musa BY, Elfaki ME, et al. (2013) Post-Kala-Azar Dermal Leishmaniasis: A Paradigm of Paradoxical Immune Reconstitution Syndrome in Non-HIV/AIDS Patients. J Trop Med 2013: 275253 doi: 10.1155/2013/275253.
[60]  Tadesse A, Hurissa Z (2009) Leishmaniasis (PKDL) as a case of immune reconstitution inflammatory syndrome (IRIS) in HIV-positive patient after initiation of anti-retroviral therapy (ART). Ethiop Med J 47: 77–79.
[61]  van GJ, Diro E, Lopez-Velez R, Boelaert M, Lynen L, et al. (2013) HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals. Lancet Infect Dis 13: 251–259 doi: 10.1016/S1473-3099(12)70348-1.
[62]  Word Health Organization (2013) Consolidated Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization.
[63]  CDC (2009) Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR Morb Mortal Wkly Rep 58: RR–4.
[64]  Hailu A, Gebre-Michael T, Berhe N, Balkew M (2006) Leishmaniasis in Ethiopia. In: The Ecology and Epidemiology of Health and Disease in Ethiopia. Addis Ababa, Ethiopia: Shama Books. pp. 615–634.
[65]  Lyons S, Veeken H, Long J (2003) Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop Med Int Health 8: 733–739. doi: 10.1046/j.1365-3156.2003.01088.x

Full-Text

comments powered by Disqus